Compare CVS Health Corp (CVS) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Tesla, Inc. — how do they compare? CVS Health Corp trades at $105.81 (market cap $135.48B), while Tesla, Inc. trades at $396.7 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 11× CVS Health Corp's market cap, and CVS Health Corp pays a 2.51% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| CVS | TSLA | |
|---|---|---|
Market Cap | $135.48B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $106.18 | $489.88 |
52-Week Low | $58.75 | $302.63 |
Enterprise Value | $202.02B | $1.46T |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Tesla (TSLA) trades at $394.76, down 3.18% today amid a bearish technical signal. The stock faces pressure from elevated valuations with a P/E of 362.17 and P/S of 14.25, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Cash flow remains positive at $579M in 2025, though net income margins have compressed to 3.95% from prior years. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.
The outlook is cautious; while analyst consensus is a Buy with a $409.26 target, risks include intense EV competition, execution on AI/robotics bets, and high valuation multiples. Near-term performance hinges on Q2 2026 earnings and delivery growth, with support at $391 and resistance at $399.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
